Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Hudan Liu, PhD, Jue Jiang, PhD, Jingchao Wang, PhD, Ming Yue, PhD, Hui Feng, MD PhD, Guoliang Qing, PhD

Blood (2019) 134 (Supplement_1): 732.

https://doi.org/10.1182/blood-2019-130112

Published: 2019

Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD

Blood (2018) 132 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2018-99-118465

Published: 2018

Journal Articles

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Wolfram Brugger, MDPhD, Susan Ashton, Carrie A. Adelman, Nicolas Floc'h, Paula Taylor, Maureen Hattersley, PhD, Shenghua Wen, Kimberly Maratea, Philip Overend, Steven Fox, Julie Charlton, Simon T Barry, Donald Strickland, MD, Suzanne Jones, PharmD, Howard A. Burris, MD, Carol Greenlees, Alexander MacDonald, J. Elizabeth Pease, PhD, William Donnellan

Blood (2017) 130 (Supplement 1): 1368.

https://doi.org/10.1182/blood.V130.Suppl_1.1368.1368

Published: 2017

Journal Articles

A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Graham P Collins, MA, PhD, Eyre A Toby, MBChB, Chris S. Hatton, MD, John Radford, Kim M Linton, MBChB, MRCP, PhD

Blood (2014) 124 (21): 4481.

https://doi.org/10.1182/blood.V124.21.4481.4481

Published: 2014

Journal Articles

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

Kam Cheung, Gloria Juan, William Wayne, Kelly Hanestad, Kathleen Keegan, Justin Huard, Patricia McElroy, Mary K Stanton, Tammy L Bush, Richard L Kendall, Robert Radinsky, Steve Abella, Peter C Pieslor, Gregory Friberg, Angela Coxon, Erick Gamelin, Marc Payton

Blood (2013) 122 (21): 3823.

https://doi.org/10.1182/blood.V122.21.3823.3823

Published: 2013

Journal Articles

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Stefanie A. Hartsink-Segers, C. Michel Zwaan, Carla Exalto, Mirjam W.J. Luijendijk, Valerie S. Calvert, Emanuel F. Petricoin, PhD, William E. Evans, PharmD, Dirk Reinhardt, MD, Válerie de Haas, Maj Hedtjärn, Bo R. Hansen, PhD, Troels Koch, PhD, Huib N. Caron, Rob Pieters, MD, PhD, Monique L. Den Boer, PhD

Blood (2012) 120 (21): 1465.

https://doi.org/10.1182/blood.V120.21.1465.1465

Published: 2012

Journal Articles

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Bob Löwenberg, Petra Muus, Gert Ossenkoppele, Philippe Rousselot, Jean-Yves Cahn, Norbert Ifrah, Giovanni Martinelli, Sergio Amadori, Ellin Berman, Pieter Sonneveld, Mojca Jongen-Lavrencic, Sophie Rigaudeau, Paul Stockman, Alison Goudie, Stefan Faderl, Elias Jabbour, Hagop Kantarjian

Blood (2011) 118 (23): 6030–6036.

https://doi.org/10.1182/blood-2011-07-366930

Published: 2011

Journal Articles

Phase I Study of the Aurora B Kinase Inhibitor Barasertib (AZD1152) to Assess the Pharmacokinetics (PK), Metabolism and Excretion in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Mike Dennis, MD, MRCP, FRCPath, Michelle Davies, RGN, BN, Stuart Oliver, MD, Roy D'Souza, BSc (Hons), Laura Pike, MSc, Paul Stockman, MD, PhD

Blood (2011) 118 (21): 2602.

https://doi.org/10.1182/blood.V118.21.2602.2602

Published: 2011

Journal Articles

Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target

Stefanie A. Segers, C. Michel Zwaan, Carla Exalto, Mirjam W.J. Luijendijk, Valerie S. Calvert, Emanuel F. Petricoin, William E. Evans, Dirk Reinhardt, MD, Rob Pieters, Monique L. Den Boer

Blood (2011) 118 (21): 1476.

https://doi.org/10.1182/blood.V118.21.1476.1476

Published: 2011

Journal Articles

A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy

Qiang Jeremy Wen, MD, PhD, Serena Silver, PhD, Tim Lewis, PhD, Sridevi Ponduru, MBBS, PhD, Vlado Dancik, phd, Ben Goldenson, Mark Bray, Anne Carpenter, PhD, Paul Clemons, PhD, David Root, phd, Andrew Stern, phd, Robert Gould, phd, John Crispino, PhD

Blood (2010) 116 (21): 89.

https://doi.org/10.1182/blood.V116.21.89.89

Published: 2010

Journal Articles

Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Mikkael A. Sekeres, MD, MS, Vincent Ribrag, MD, Philippe Rousselot, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Kate Owen, MBChB, Paul Stockman, MD, PhD, Stuart Oliver, MFPM

Blood (2010) 116 (21): 656.

https://doi.org/10.1182/blood.V116.21.656.656

Published: 2010

Journal Articles

Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process

Larissa Lordier, Yunhua Chang, Abdelali Jalil, Frédéric Aurade, Loïc Garçon, Yann Lécluse, Frédéric Larbret, Toshiyuki Kawashima, Toshio Kitamura, Jérôme Larghero, Najet Debili, William Vainchenker

Blood (2010) 116 (13): 2345–2355.

https://doi.org/10.1182/blood-2010-01-265785

Published: 2010

Journal Articles

Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.

Bob Lowenberg, MD, PhD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, Alison Goudie, Paul Stockman, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2080.

https://doi.org/10.1182/blood.V114.22.2080.2080

Published: 2009

Journal Articles

Analysis of Aurora B Kinase in Non-Hodgkin’s Lymphoma.

Takayuki Ikezoe, Tamotsu Takeuchi, Chie Nishioka, Yoshihiro Adachi, Mutsuo Furihata, H. Phillip Koeffler, MD, Akihito Yokoyama

Blood (2008) 112 (11): 1610.

https://doi.org/10.1182/blood.V112.11.1610.1610

Published: 2008

Journal Articles

The Effect of ABC Transporters and FLT3 Status on the Activity of the Aurora Kinase B Inhibitor AZD1152 in AML Cells.

Martin Grundy, BSc, Shili Shang, MD, MSc, C. Seedhouse, PhD, Nigel H. Russell, MD, Monica Pallis, PhD

Blood (2008) 112 (11): 1627.

https://doi.org/10.1182/blood.V112.11.1627.1627

Published: 2008

Journal Articles

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

Jing Yang, Takayuki Ikezoe, Chie Nishioka, Taizo Tasaka, Ayuko Taniguchi, Yoshio Kuwayama, Naoki Komatsu, Kentaro Bandobashi, Kazuto Togitani, H. Phillip Koeffler, Hirokuni Taguchi, Akihito Yokoyama

Blood (2007) 110 (6): 2034–2040.

https://doi.org/10.1182/blood-2007-02-073700

Published: 2007

Journal Articles

The Specific Aurora Kinase Inhibitor AZD1152 Significantly Affects the Growth of Human Leukaemic Cells in an In Vivo AML Model.

Daniel Pearce, Rajesh Odedra, Robert Wilkinson, Dominique Bonnet

Blood (2006) 108 (11): 162.

https://doi.org/10.1182/blood.V108.11.162.162

Published: 2006

Journal Articles

ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo .

Mark R. Bray, PhD, Graham C. Fletcher, PhD, Trisha A. Denny, John Xu, PhD, Xiaoru Chen, Patricia A. Burke, PhD, Wanda Franklin, Theresa M. LaVallee, PhD, Mark D. Minden, MD, PhD, Carolyn F. Sidor, MD, MBA

Blood (2006) 108 (11): 1377.

https://doi.org/10.1182/blood.V108.11.1377.1377

Published: 2006

Journal Articles

Aurora Kinases as Therapeutic Targets in Multiple Myeloma.

Tony Reiman, Robert P. Evans, Claudia Naber, Tara Steffler, Jonathan J. Keats, Troy Perry, Christopher A. Maxwell, Heidi Chau, Andrew R. Belch, Linda M. Pilarski

Blood (2006) 108 (11): 847.

https://doi.org/10.1182/blood.V108.11.847.847

Published: 2006

NARROW

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo

The Potential of Aurora Kinases A and B As Therapeutic Targets in Pediatric Acute Leukemia

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

Phase I Study of the Aurora B Kinase Inhibitor Barasertib (AZD1152) to Assess the Pharmacokinetics (PK), Metabolism and Excretion in Patients (pts) with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Aurora Kinases in Childhood Acute Leukemia: The Promise of Aurora Kinase B As Drugable Target

A Kinome shRNA Screen to Identify Pathways That Regulate Megakaryocyte Polyploidization and New Targets for Differentiation Therapy

Phase I Study to Assess the Safety and Tolerability of AZD1152 In Combination with Low Dose Cytosine Arabinoside In Patients with Acute Myeloid Leukemia (AML)

Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process

Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia.

Analysis of Aurora B Kinase in Non-Hodgkin’s Lymphoma.

The Effect of ABC Transporters and FLT3 Status on the Activity of the Aurora Kinase B Inhibitor AZD1152 in AML Cells.

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

The Specific Aurora Kinase Inhibitor AZD1152 Significantly Affects the Growth of Human Leukaemic Cells in an In Vivo AML Model.

ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo .

Aurora Kinases as Therapeutic Targets in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only